The earnings call highlighted Kenvue's challenges, including disappointing Q2 results, operational complexity, and soft market conditions. However, efforts to strengthen leadership and improve specific brand performances provide some positive outlook. Despite these efforts, the significant challenges and revised guidance indicate a cautious sentiment.

Company Guidance -

Q3 2025

During Kenvue's Second Quarter 2025 Earnings Conference Call, the company provided revised guidance for the year, indicating that organic sales are expected to decline in the low single digits, with about a neutral impact from currency. The call revealed that the company's top-line results for Q2 were below expectations, with organic sales declining by 4.2%. This was attributed to factors such as unfavorable seasonal and customer inventory dynamics, particularly in the Self Care segment, as well as strategic price investments and trade inventory fluctuations. The adjusted operating margin contracted slightly by 10 basis points to 22.7%. Kenvue's leadership emphasized a focus on improving execution, optimizing the brand portfolio, and making strategic investments to enhance financial performance, with adjusted diluted EPS projected to be in the range of $1 to $1.05. The company is undertaking a comprehensive review of strategic alternatives to unlock shareholder value and drive growth.

Leadership and Capability Strengthening

Kenvue has appointed 4 new leaders to its leadership team over the past 3 months, enhancing capabilities in marketing, sales, digital, and AI across markets.

Sequential Improvement in Specific Segments

Neutrogena Face showed sequential improvement in consumption trends. Additionally, Tylenol has seen 12 consecutive quarters of share improvement in the U.S.

Encouraging Regional Performance

Performance in EMEA and Latin America has been positive, with strong focus and executional elements achieving better results.

Strong Brand Portfolio

Kenvue's iconic brand portfolio, such as Tylenol and Nicorette, continues to show potential for growth with strong execution and innovation.

Kenvue, Inc. (KVUE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

KVUE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 23, 2025	2025 (Q3)	0.27 / -	0.28	―	―	―
Jul 14, 2025	2025 (Q2)	0.28 / 0.29	0.32	-9.38% (-0.03)	―	―
May 08, 2025	2025 (Q1)	0.23 / 0.24	0.28	-14.29% (-0.04)
Feb 06, 2025	2024 (Q4)	0.26 / 0.26	0.31	-16.13% (-0.05)
Nov 07, 2024	2024 (Q3)	0.27 / 0.28	0.31	-9.68% (-0.03)
Aug 06, 2024	2024 (Q2)	0.28 / 0.32	0.32	0.00% (0.00)
May 07, 2024	2024 (Q1)	0.25 / 0.28	0.33	-15.15% (-0.05)
Feb 08, 2024	2023 (Q4)	0.28 / 0.31	0.28	10.71% (+0.03)
Oct 26, 2023	2023 (Q3)	0.31 / 0.31	0.31	0.00% (0.00)
Jul 20, 2023	2023 (Q2)	0.30 / 0.32	0.315	1.59% (<+0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

KVUE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 14, 2025	$21.34	$21.82	+2.25%
May 08, 2025	$22.91	$23.85	+4.10%
Feb 06, 2025	$20.36	$19.44	-4.52%
Nov 07, 2024	$21.89	$22.35	+2.10%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.